Yangyun
Wang
a,
Guolin
Wu
*a,
Xiaomeng
Li
a,
Yinong
Wang
a,
Hui
Gao
b and
Jianbiao
Ma
*ab
aKey Laboratory of Functional Polymer Materials of MOE, Institute of Polymer Chemistry, Nankai University, Tianjin 300071, P. R. China. E-mail: guolinwu@nankai.edu.cn; Fax: +86 22 23502749; Tel: +86 22 23507746
bSchool of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin 300191, P. R. China. E-mail: jbma@tjut.edu.cn; Fax: +86 22 23502749; Tel: +86 22 23507746
First published on 8th March 2013
A novel on–off switchable drug-release system was developed based on a series of multi-responsive degradable poly(ether urethane)s. The multi-segmented poly(ether urethane)s were synthesized through a simple one-pot condensation polymerization of poly(ethylene glycol), 2,2′-dithiodiethanol, N-methyldiethanolamine and hexamethylene diisocyanate. The obtained amphiphilic copolymers could self-assemble into nanoparticles in aqueous solution, which were responsive to temperature, pH and redox potential with tailored phase-transition temperature. The whole process for the responsive behaviours of the poly(ether urethane) nanoparticles was confirmed by light transmission, dynamic light scattering, nuclear magnetic resonance and transmission electron microscopy. The nanoparticles could encapsulate hydrophobic drugs and showed a temperature-triggered accelerated and complete drug-release profile. The mechanism of the temperature-triggered multi-responsive accelerated drug release was also elucidated. These results presented the polymeric nanoparticles as an effective multi-responsive degradable nanocarrier to achieve on–off drug release.
An ideal on–off drug delivery carrier should release little or no drugs in the “off” state, and be reproducibly switchable to the “on” state without mechanical disruption, and then release a tunable dosage of drugs.10 To meet the above requirements, employing temperature-responsive polymers as drug carriers could be a promising way for the successful development of on–off switchable drug-delivery carriers.10,11 Recently, temperature-responsive polymeric systems encapsulating gold or iron oxide nanoparticles have been developed for on–off controlled drug release that exhibit sensitivity to non-invasive external triggers such as near-infrared radiation12–14 or oscillating magnetic fields.15–17 In these cases, the external energy can be converted into heating, and thus on–off switchable drug release can be triggered remotely to provide the proper dose magnitude and timing according to the patient's needs.18
However, single temperature-responsive carriers always result in transient drug release due to the slow polymer degradation and fast completion of phase transition, which cannot provide a high drug bioavailability.19,20 An alternative solution is to develop multi-responsive degradable polymeric carriers to achieve the complete drug release. Nevertheless, limited multi-responsive polymeric carriers are reported, not to mention the multi-responsive degradable ones.21–26 Thayumanavan et al. reported a triple-stimuli-responsive polymeric micelle which comprised an acid-sensitive hydrophobic core, a temperature-sensitive hydrophilic shell and a redox-sensitive interface.27 The system demonstrated the feasibility of combining different orthogonal triggers and provided a unique opportunity to release the encapsulated drug completely.
Recently, a series of poly(ether urethane) nanoparticles based on alternative hydrophilic and hydrophobic segments has been developed in our group, which exhibited reversible temperature responsiveness with the phase-transition temperature (Tp) adjusted in the range of 30–40 °C.28,29 Giving further credence to this approach, we have reported a series of dually responsive poly(ether urethane) nanoparticles which exhibited temperature-triggered redox-degradable behaviour.30 Inspired by these promising results, we envisaged the possibility of designing an effective on–off switchable drug-release system based on a series of segmented poly(ether urethane)s (denoted as SPU) by repeatedly incorporating both pH- and redox-responsive segments into the temperature-responsive poly(ether urethane) backbones. In this system, (1) temperature is designed to be used as the remote means of triggering on–off drug release, and (2) redox and pH responsiveness are used to enhance the release rate and bioavailability of the drug which only play a role in the ‘open state’ of drug release. The ability to use temperature to regulate multi-responsive behaviour in a single system is considered to be highly advantageous for future exploitation in biomedical fields. To the best of our knowledge, this is the first time an on–off switchable drug-release system based on multi-responsive polymers has been reported.
A certain amount of DiT (0.5 mmol) and MDEA (1.5 mmol) was dissolved in a mixture of 1,2-dichloroethane and THF (20 mL, CH2ClCH2Cl:THF = 5:1). Then the mixture was added dropwise into the ready prepared PEG-diisocyanate (2 mmol) solution with stannous octanoate as the catalyst (0.5 wt%, with respect to the reactant). The reaction was performed at 80 °C under dry nitrogen atmosphere. After 24 h, an excess amount of methanol was added and stirred for 1 h to eliminate the stannous octanoate residue and oligomers. The production was then precipitated in diethyl ether. The resulting product was collected through filtration, followed by drying under vacuum to constant weight, affording a yield of over 80%.
The critical micelle concentration (CMC) of SPU2 is around 0.02 mg mL−1 at 25 °C, measured by fluorescence spectrometry using pyrene as a probe (Fig. S1 in the ESI†). The CMC of the other polymers have similar values. The concentration of polymer solutions used in the following measurements is 1 mg mL−1, which is much higher than their CMC.
The particle size and distribution (PDI) in response to temperature were determined by dynamic light scattering (DLS) using Zetasizer Nano ZS90 (Malvern Instruments, Southborough, MA). Measurements were carried out at special temperatures in the range from 20 to 70 °C during the heating and cooling process and equilibrated for 15 min before each measurement. In the present DLS study, the normalized field–field autocorrelation function |g(1)(τ)| (≡ [〈E(0) − E*(τ)〉/〈E(0)E*(0)〉]) of each copolymer solution at different temperature was measured at the scattering angle θ = 90°. For a polydisperse sample, g(1)(τ) is related to the distribution of the characteristic line width G(Γ) by:
(1) |
For a diffusive relaxation, Γ is related to the translational diffusion coefficient D by Γ = Dq2, when the solution is in dilute regime. In principle, G(Γ) can be calculated from the Laplace inversion according to eq (1). D is further related to the hydrodynamic radius Rh by Rh = kBT/(6πη0D). The well-accepted Laplace inversion CONTIN algorithm was used in the analysis of the DLS autocorrelation curves.32,33
The zeta potential, particle size and distribution in response to pH of the nanoparticles were also recorded using a Zetasizer Nano ZS90 Malvern instrument.
The temperature-triggered on–off switchable drug-release studies were performed as follows: the “ON” state was triggered by placing the screw-cap jars with DOX-loaded SPU2 nanoparticles in phosphate-buffered saline (PBS, pH 6.0 or 7.4) in a 37 °C water bath. After incubation for a period of time, the above screw-cap jars was taken out and placed in a 25 °C water bath which was defined as the “OFF” state. This process was carried out for several cycles and fluorescence at different time intervals was recorded to get the “ON” and “OFF” profiles.
The segmented poly(ether urethane)s could be easily synthesized in two different ways. Scheme 1 illustrates the synthesis route of PEG-alt-(MDEA/DiT) copolymers based on condensation reaction between different molecular weight PEG-diisocyanates and two diols with pH and redox responsive groups. The parent PEG-diisocyanates with different molecular weights were prepared by coupling reaction using 1 equiv. PEG and 2 equiv. HDI. A typical 1H NMR spectrum of PEG-diisocyanates is shown in Fig. 1(A). The 1HNMR results confirm the formation of the PEG-diisocyanate. Scheme 2 illustrates the synthesis route of PEG-co-(MDEA/DiT) copolymers based on one-pot condensation reaction between DiT, MDEA, PEG and HDI. The second approach is more convenient to adjust their hydrophilic/hydrophobic balance based on different monomer feedings, which is crucial for the control of its phase-transition temperature. All synthesized multi-block copolymers consisted of PEG and HDI as hydrophilic and hydrophobic segments, respectively. Disulfide bonds and tertiary amines served as stimuli-responsive moieties. The synthesized polymers were characterized by 1HNMR, FT-IR and GPC. A typical SPU2 1HNMR spectrum of the obtained polymers is shown in Fig. 1(B). In addition to the typical peaks of PEG-diisocyanate, the characteristic peaks corresponding to the MDEA and DiT segments were observed in Fig. 1(B). The representative FT-IR spectra of the multi-block poly(ether urethane) SPU2, and PEG-diisocyanate, DiT and MEDA are shown in Fig. 2. For the segmented copolymer, the bands at 1715 and 3331 cm−1 are assigned to the CO and N–H stretching of urethane groups, respectively. The absence of absorbance at 2272 cm−1 indicates no isocyanate groups in the resulting polymer. The typical GPC trace of PEG and the corresponding SPU are shown in Fig. S2 in the ESI.† A unimodal GPC peak was observed for the obtained polymer. The characterization results of all synthesized segmented copolymers are collected in Table 1.
Scheme 1 Synthesis of the PEG-alt-(MDEA/DiT) copolymers. |
Fig. 1 (A) 1H NMR spectrum of PEG-diisocyanate (Mw = 1000) in CDCl3. (B) 1H NMR spectrum of the segmented poly(ether urethane) SPU2 in DMSO-d6. |
Scheme 2 Synthesis of the PEG-co-(MDEA/DiT) copolymers. |
Fig. 2 FTIR spectra of MDEA, DiT, PEG-diisocyanate (Mw = 1000) and the segmented poly(ether urethane) SPU2. |
Sample code | Copolymer composition | PEG Mn | R (MDEA:DiT)c | R 1 (PEG:(MDEA + DiT))d | Polymer | ||
---|---|---|---|---|---|---|---|
M ne | PDIf | T pg (°C) | |||||
a PEG-alt-(MDEA/DiT) copolymers based on PEG-diisocyanate and (MDEA/DiT). b PEG-co-(MDEA/DiT) copolymers based on PEG, HDI and (MDEA/DiT). c MDEA:DiT molar ratio in feed. d PEG:(MDEA + DiT) molar ratio in feed. e Determined by GPC in THF. f Polydispersity index. g T p was determined from the onset of the decrease in the transmittance of the polymer aqueous solution or from the onset of the increase in the hydrodynamic diameter of the polymer aqueous solution. | |||||||
SPU1 | PEG600-alt-(MDEA–DiT)a | 600 | 3:1 | 1:1 | 12352 | 1.76 | 25 |
SPU2 | PEG1000-alt-(MDEA–DiT)a | 1000 | 3:1 | 1:1 | 32685 | 1.43 | 35 |
SPU3 | PEG1500-alt-(MDEA–DiT)a | 1500 | 3:1 | 1:1 | 19556 | 1.52 | 55 |
SPU4 | PEG2000-alt-(MDEA–DiT)a | 2000 | 3:1 | 1:1 | 32069 | 1.61 | 60 |
SPU5 | PEG1000-co-(MDEA–DiT) (2:1)b | 1000 | 3:1 | 2:1 | 23542 | 1.49 | 40 |
SPU6 | PEG1000-co-(MDEA–DiT) (3:1)b | 1000 | 3:1 | 3:1 | 69531 | 1.49 | 45 |
Fig. 3 Photographs showing an aqueous solution of SPU1 under different conditions. |
Fig. 4 (A) Temperature-dependence of the transmittance (a) and the hydrodynamic diameter (b) of the SPU1 aqueous solution. (B) The size change of SPU1 under different temperatures in aqueous solution. (C) TEM graphs for SPU1 nanoparticles under different temperatures in aqueous solution: (a) 20 °C; (b) 37 °C; (c) 55 °C. |
To further understand the temperature-responsive aggregation of the SPU nanoparticles, the size distribution of the SPU1 in aqueous solution under different temperatures is also given in Fig. 4B. At 37 or 55 °C, which was above its Tp of the copolymer, a sharp increase in the average effective diameter of nanoparticles was presented compared with at 20 °C, which is below its Tp. This is because above the Tp the hydrogen bonds between PEG and water molecules are weaker and a part of water molecules are expelled from the polymer chains and the interaction between the hydrophobic units of the polymers becomes stronger and results in the aggregation of the polymer nanoparticles and turbidity of the solution. The behaviour of the temperature-responsive aggregation of SPU1 nanoparticles at the corresponding temperature was further investigated using TEM images (Fig. 4C). The morphologies of the polymer particles at different stages of the aggregation process during heating were observed. Almost uniform-sized spherical nanoparticles of 200 nm were found at 20 °C, below its Tp (Fig. 4Ca). When above Tp, large aggregations were formed with a diameter of about 400 and 600 nm at 37 and 50 °C (Fig. 4Cb and c), respectively. These results are in good accordance with the DLS measurements.
The size distribution of SPU2 (Tp, 35 °C) in aqueous solution at different temperatures is also illustrated in Fig. S3 in the ESI.† At 25 °C, a single peak around 200 nm was observed. With an increase of temperature to 45 °C, a new distribution above 1000 nm appeared which indicates of the aggregation of nanoparticles into microparticles at this temperature. It is known that increase in the length of the hydrophilic segments or ratio of hydrophilic/hydrophobic segments would increase the Tp of the polymer.35,36 From the Fig. S4 and S5 in the ESI,†Tp was indeed strongly affected by the polymer composition. The SPU2–SPU4 containing longer hydrophilic PEG segments (Mw = 1000, 1500 or 2000 Da) and the SPU5 and SPU6 with a higher ratio of hydrophilic/hydrophobic segments exhibited higher Tp compared with SPU1. The heating–cooling cycle of SPU2 aqueous solution was also conducted (Fig. S6 in the ESI†). The results showed that the cooling curve was very close to the heating curve, indicating a good reversibility of the temperature-responsive phase transition process. The reversibility of the temperature responsiveness for the nanoparticles during the heating–cooling cycling was also investigated via light scattering. The DLS results show excellent reversibility similar to the turbidity/transmission results. A typical hydrodynamic radius distribution and corresponding TEM images of blank SPU2 nanoparticles at 25 °C during the heating and cooling process are shown in Fig. S7B and S7C in the ESI.† The corresponding field–field autocorrelation functions of blank SPU2 nanoparticles were also given to support the DLS results (Fig. S7A in the ESI†). The hydrodynamic radius distribution was calculated by using the well-accepted Laplace inversion CONTIN algorithm. These results reveal that the phase transition of PEG analogues is much more uniform than that of poly(N-isopropylacrylamide) (PNIPAM), which has a significant hysteresis observed in the cooling process.37
To assess whether such a transition in response to temperature would result in the concomitant release of the encapsulated agents, DOX-loaded SPU2 nanoparticles were prepared to perform release experiments. The mixture of SPU2 and DOX solution was dialyzed against the deionized water in the dark until the water outside the dialysis tube exhibited negligible fluorescence emission of DOX. This dialysis process guaranteed the removal of the non-entrapped DOX molecules. The size of drug-loaded nanoparticles is an important factor affecting their stability, in vivo distribution, cellular internalization, and the intracellular fate. By dynamic light scattering (DLS) measurements (Fig. 5A and B), the average hydrodynamic diameter of the blank SPU2 nanoparticles in an aqueous solution was about 230 nm, while the size of the DOX-loaded SPU2 nanoparticles was about 300 nm. The increase in average size of the particles is caused by the drug molecules that have been entrapped. TEM micrographs revealed that the nanoparticles had an almost spherical morphology with an average size of about 250 nm for the blank nanoparticles (Fig. 5C) and about 300 nm for the DOX-loaded nanoparticles (Fig. 5D). The drug loading content and entrapment efficiency were calculated to be 15.6% and 91.2%, respectively.
Fig. 5 (A) and (C) DLS and TEM images of blank SPU2 nanoparticles. (B) and (D) DLS and TEM images of DOX-loaded SPU2 nanoparticles. |
The drug-loaded polymeric solution was treated under different temperatures (25, 37 and 50 °C) at pH = 7.4. The release of DOX from the nanoparticles was monitored as a function of time and is depicted in Fig. 6. At 25 °C, a slow release of DOX was observed and only about 24% of the drug was released in 2 days. Therefore, below the Tp, the release rate is very sluggish. At 37 °C, around Tp, an accelerated drug release was observed compared with that at 25 °C and 33% of the drug was released in 2 days. When temperature was increased above Tp at 50 °C, the drug-release rate increased dramatically and more than 40% of DOX was released out in 10 h. This suggests the faster release kinetics of DOX at higher temperature above Tp with concomitant aggregation of nanoparticles. While below the Tp, the release rate is very sluggish. It should be noted that, as shown in Fig. 6, the drug release was shut down in a short period of time with the completion of phase transition. After 10 hours only a very small amount of drug was released continuously. Therefore, temperature can be used as a switch to trigger the drug release in this system. However, single temperature-induced drug delivery cannot provide a high drug bioavailability.
Fig. 6 In vitro release of doxorubicin from the SPU2 nanoparticles in PBS (pH 7.4) at different temperatures. |
Fig. 7 (A) pH-dependence of the transmittance (a) and zeta potential (b) of SPU1 aqueous solution under different pH values at 20 °C. (B) The size change of SPU1 under different pH at 20 °C. (C) TEM graphs of SPU1 under different pH at 20 °C: (a) pH = 7.0; (b) pH = 3; (c) pH = 11. |
The SPU nanoparticles were also monitored using DLS measurements. The SPU1 solution (1 mg mL−1) was dissolved in phosphate buffer with different pH values (pH = 3, 7.0 or 11). As shown in Fig. 7B, the size of the nanoparticle increased at both higher or lower pH conditions compared with the physiological condition (pH 7.4). Fig. 7C shows the corresponding TEM images of the nanoparticles, which also showed larger particles under the treatment of H+ or OH−. However, the mechanisms of particle size increase at these two conditions are different. When nanoparticles were in acidic conditions, particle size increased from 282 nm (Fig. 7Ca) to 1455 nm (Fig. 7Cb) and scattering intensity (kcps) decreased sharply from 166 to 67 (not shown). This is because at acidic condition ternary amino moieties in MDEA segments are protonated and changed to become more hydrophilic, leading to the nanoparticles transforming from dense to swollen structures or even dissolving. When the solution was in basic conditions, particle size increased from 282 nm to 1736 nm (Fig. 7Cc) and scattering intensity (kcps) increased from 166 to 250 (not shown). This is because at basic condition ternary amino moieties are completely deprotonated, resulting in increasing of intermolecular hydrophobic interactions and aggregation of the nanoparticles.
In vitro drug-release studies of the DOX-loaded nanoparticles were performed under physiological conditions (pH 7.4) and slightly acidic environments (pH = 6.0) at 37 °C to simulate the tumor microenvironment. The release profiles of DOX are shown in Fig. 8. The drug release from nanoparticles at pH = 7.4 was considerably slow, with a release of about 33% in 48 h. On the contrary, the drug release was faster at pH 6.0, with approximately 51% of the drug released within 48 h for pH 6.0. The change in pH from 7.4 to 6.0 leads to swelling or disassembly of nanoparticles, thereby causing the release of the enclosed drug.
Fig. 8 In vitro release of doxorubicin from SPU2 nanoparticles at different pH at 37 °C. |
The size change of SPU1 nanoparticles in response to GSH was monitored by DLS measurements. Briefly, GSH was added to 1.5 mL of nanoparticle solution in PBS (10 mM, pH 7.4) to yield a final GSH concentration of 10 mM, which is a typical intracellular concentration. At different time intervals, the light-scattering intensity and the nanoparticle sizes were measured using DLS at 37 °C. The light-scattering intensity decreased sharply after treatment with 10 mM GSH for 5 min, while the SPU1 nanoparticles maintain similar scattering intensity for 1 h without the GSH treatment (Fig. 9A). In the presence of GSH, the quick dissociation of the nanoparticles and bimodal and broad size distribution were observed instead of uniform and narrow size distribution at the same temperature (37 °C) (Fig. 9B). TEM images for SPU1 nanoparticles treated with GSH are shown in Fig. 9C and irregularly shaped nanoparticles of varying sizes were found due to the dissolution of polymeric particles. As the disulfide bonds are broken, the particles dissociate and dissolve. As a result, the turbid solution changed to be transparent (Fig. 3). The bimodal and broad size distribution is probably due to the remaining debris of the dissociated particles. The result is in good agreement with the drastic decrease in scattering intensity.
Fig. 9 (A) Redox-triggered scattering intensity changes of SPU1 aqueous solution under different conditions. (B) Reduction-triggered changes of SPU1 nanoparticle size distributions. (C) TEM graphs of SPU1 nanoparticles treated with GSH in aqueous solution: (a) 37 °C without GSH, (b) 37 °C with 10 mM GSH for 1 h, (c) 37 °C with 10 mM GSH for 2 h. |
Along the same lines, the release of DOX from nanoparticles was investigated under the effect of glutathione. In Fig. 10, at a concentration of 10 mM glutathione, it showed a persistent increase over a long time. About 80% of DOX was released in 2 days. And only 32% release was observed without GSH over the same period of time. This is because as the disulfide cleaves under GSH, polymers are degraded and the encapsulated drugs are released. Note that the intracellular glutathione concentrations have been estimated to be as high as 10 mM, while the concentration is even higher in tumor cells. It suggests that the polymeric nanoparticles respond to redox stimulus well and are suitable to be used as redox-responsive release carriers.
Fig. 10 In vitro release of doxorubicin from SPU2 nanoparticles at different concentrations of GSH at 37 °C and pH = 7.4. |
The purpose of this study is to integrate multiple stimuli-responsive properties into a single macromolecular carrier, which could provide an opportunity to fine-tune the release kinetics of encapsulated agents and obtain a desired release profile at specific circumstances through the synergistic effect of these stimuli. First, the responsiveness of the nanoparticles to pH, temperature and redox potential has been confirmed independently. The release kinetics of DOX from the polymer nanoparticles was found to be incomplete or slow when a temperature, pH or redox potential stimulus was applied by itself. In this system, all these three stimuli-responsive functionalities were incorporated into a single particle. To test the synergistic effect of these stimuli, the DOX-encapsulating SPU2 nanoparticles were subjected to glutathione (10 mM) in acetate buffer (pH 6.0) at 37 °C. The release profile of DOX was monitored and plotted against time (Fig. 11). A dramatic increase in the release rate of DOX was observed and almost 100% of the drug was released within 48 h. In aqueous solution, poly(ether urethane)s are dispersed as nanoparticles, where HDI, MDEA and DiT segments serve as cores and PEG segments serve as hydrophilic shells. Hydrophobic drugs could be loaded into the core of the nanoparticles via hydrophobic interactions. When above Tp, the PEG segments dehydrate and shrink to the hydrophobic cores and the nanoparticles aggregate, and more disulfide bonds and ternary amino moieties are exposed to react with GSH and H+, respectively. The pH-induced particle disassembly would allow more GSH to go into the particles to react with disulfide linkages. All these accelerate the particle dissociation and cause a fast and complete drug release at higher temperature.
Fig. 11 In vitro release of doxorubicin from the SPU2 nanoparticles under different conditions: (a) 37 °C, pH = 7.4; (b) 37 °C, pH = 6.0; (c) 37 °C, pH = 7.4, 10 mM GSH; (d) 37 °C, pH = 6.0, 10 mM GSH. |
Fig. 12 (A) Variable-temperature 1H NMR spectra of SPU2 at pH = 7.4. (B) Variable-pH 1H NMR spectra of SPU2 at 25 °C. |
Fig. 13 In vitro pulsatile release of doxorubicin from multi-responsive SPU2 nanoparticles under pH = 6.0, 10 mM GSH where the temperature is varied between 25 and 37 °C. |
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3bm00188a |
This journal is © The Royal Society of Chemistry 2013 |